Natural history of hepatitis C.
暂无分享,去创建一个
A. Alberti | A Alberti | L Chemello | L Benvegnù | L. Benvegnu' | L. Chemello | Liliana Chemello | Luisa Benvegnù
[1] A. Valleron,et al. Modeling the hepatitis C virus epidemic in france , 1999, Hepatology.
[2] A Sette,et al. Presence of effector CD8+ T cells in hepatitis C virus-exposed healthy seronegative donors. , 1999, Journal of immunology.
[3] J. Puel,et al. Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection. , 1997, Gastroenterology.
[4] G. Gerken,et al. MHC class II genes influence the susceptibility to chronic active hepatitis C. , 1997, Journal of hepatology.
[5] E. Kenny‐Walsh. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. , 1999, The New England journal of medicine.
[6] A. Alberti,et al. Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus‐related cirrhosis , 1997, Hepatology.
[7] M A Gerber,et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. , 1992, The New England journal of medicine.
[8] B. Walker,et al. Hepatitis C virus-specific cytolytic T lymphocyte and T helper cell responses in seronegative persons. , 1997, The Journal of infectious diseases.
[9] R. Canet,et al. Histological evolution of chronic hepatitis C. Factors related to progression. , 2008, Liver.
[10] J B Wong,et al. Estimates of the Cost-Effectiveness of a Single Course of Interferon-2b in Patients with Histologically Mild Chronic Hepatitis C , 1997, Annals of Internal Medicine.
[11] D. Häussinger,et al. Prognosis of chronic hepatitis c: Results of a large, prospective cohort study , 1998, Hepatology.
[12] G. Rassidakis,et al. Histopathology of chronic hepatitis C in relation to epidemiological factors. , 1996, Journal of hepatology.
[13] C. Ferrari,et al. Hepatitis C virus viremia following clinical resolution of acute hepatitis C. , 1994, Journal of hepatology.
[14] G. Norkrans,et al. Long-term follow-up of chronic hepatitis non-A, non-B--with special reference to hepatitis C. , 2008, Liver.
[15] E. Tanaka,et al. Persistence of viremia in patients with type-C chronic hepatitis during long-term follow-up. , 1992, Scandinavian journal of gastroenterology.
[16] H. Thomas,et al. Therapies for Viral Hepatitis , 1998 .
[17] A. Alberti,et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. , 1992 .
[18] C. Gil,et al. Persistent hepatitis C viremia after acute self‐limiting posttransfusion hepatitis C , 1995, Hepatology.
[19] O. Chazouilleres,et al. Determinants of outcome of compensated hepatitis C virus‐related cirrhosis , 1998, Hepatology.
[20] F. Iber,et al. Long-Term Mortality after Transfusion-Associated Non-A, Non-B Hepatitis , 1992 .
[21] J. Bronowicki,et al. Lymphocyte reactivity to hepatitis C virus (HCV) antigens shows evidence for exposure to HCV in HCV-seronegative spouses of HCV-infected patients. , 1997, The Journal of infectious diseases.
[22] O. Yokosuka,et al. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: A prospective study of 251 patients , 1995, Hepatology.
[23] J. Pawlotsky,et al. Epidemiological factors affecting the severity of hepatitis C virus‐related liver disease: A French survey of 6,664 patients , 1997, Hepatology.
[24] P. Donaldson,et al. Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia. , 1998, Journal of hepatology.
[25] H. Margolis,et al. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease , 1998 .
[26] O. Weiland,et al. Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers. , 2008, Liver.
[27] H. Hsu,et al. A clinicopathologic study of chronic non-A, non-B (type C) hepatitis in Taiwan: comparison between posttransfusion and sporadic patients. , 1994, Journal of hepatology.
[28] M. Tong,et al. Clinical outcomes after transfusion-associated hepatitis C. , 1995, The New England journal of medicine.
[29] J. García-Samaniego,et al. Management of chronic hepatitis C in HIV-infected patients. , 1999, AIDS.
[30] E. Tanaka,et al. The natural course of chronic hepatitis C: A comparison between patients with genotypes 1 and 2 hepatitis C viruses , 1996, Hepatology.
[31] T. Tsuji,et al. Natural course of chronic hepatitis C. , 1993, The American journal of gastroenterology.
[32] H. Blum,et al. Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV). , 1990, Journal of hepatology.
[33] J. Ludwig,et al. The long‐term pathological evolution of chronic hepatitis C , 1996, Hepatology.
[34] R. Koretz,et al. Non-A, Non-B Post-Transfusion Hepatitis: Looking Back in the Second Decade , 1993, Annals of Internal Medicine.
[35] A. Widell,et al. The importance of cofactors in the histologic progression of minimal and mild chronic hepatitis C. , 2008, Liver.
[36] A. Bhalla,et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. , 1997, Gastroenterology.
[37] K. Ishak,et al. Long‐term clinical and histopathological follow‐up of chronic posttransfusion hepatitis , 1991, Hepatology.
[38] Terry Therneau,et al. Cost-Effectiveness of 6 and 12 Months of Interferon- Therapy for Chronic Hepatitis C , 1997, Annals of Internal Medicine.
[39] P. Bedossa,et al. Natural history of liver fibrosis progression in patients with chronic hepatitis C , 1997, The Lancet.